Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.
Daniel M GeynismanMauricio BurottoCamillo PortaCristina SuarezMaria T BourlonStephen HuoViviana Del TejoElla X DuXiaoran YangKeith A BettsToni K ChoueiriBradley Alexander McGregorPublished in: Clinical drug investigation (2022)
Nivolumab plus cabozantinib was associated with lower costs of grade 3/4 AE management PPPM than sunitinib, which accumulated over the 18-month study period.